Research
Energy balance
In SURMOUNT-3, the mean percentage weight change for the maximum tolerated dose of tirzepatide was -26.1% from randomization to 72 weeks among participants using weight-inducing medications.
Practitioners can consider higher doses of tirzepatide for significant weight loss in patients on weight-inducing medications.
StrongSupportsmedium confidence
The mean percentage weight change...was -26.1% (95% CI, -30.0% to -22.3%) for the maximum tolerated dose in SURMOUNT-3.
Why this rating
Based on the post hoc analysis of phase 3 randomized clinical trials.
Source
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications
Rodolfo J. Galindo et al. · JAMA Network Open · 2026
DOI 10.1001/jamanetworkopen.2026.3274
rct · n=2539
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide treatment was associated with a mean percentage weight change of -13.3% for 5 mg and -21.3% for 15 mg compared to placebo from randomization to 72 weeks among participants using weight-inducing medications in SURMOUNT-1.Strong
- Tirzepatide treatment was associated with weight loss comparable to primary study results among participants taking weight-inducing medications.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →